Bacil Pharma Limited has scheduled a board meeting for June 26, 2026, to evaluate proposals for raising funds through one or more permissible modes. The meeting will be held at the company's registered office in Mumbai to consider financial strategies subject to statutory and regulatory approvals.

The board will assess options including a preferential issue, which may involve the allotment of equity shares and/or convertible securities, and a rights issue. Other permissible modes or combinations thereof may also be considered in accordance with the Companies Act, 2013, and relevant SEBI regulations, including the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

In conjunction with the meeting, the company has announced the closure of its trading window for all designated persons and their immediate relatives. This measure is effective immediately and will remain in place until 48 hours after the declaration of the board meeting's outcome, in compliance with the company's Code of Conduct for Prevention of Insider Trading and the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The board may also consider any other business placed before it with the permission of the Chairman. The outcome of the meeting will be communicated to the stock exchanges in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Agenda Items

bacil pharma proposes to incorporate a wholly-owned subsidiary named Bacil Research & Development Private Limited to strengthen its research and development capabilities. The new entity will be established as a private limited company and will focus on undertaking R&D activities and other allied operations permitted under applicable laws. The incorporation is subject to approval from the Registrar of Companies and other relevant statutory authorities.

The Board of Bacil Pharma Limited has identified the need for a dedicated subsidiary to drive its research initiatives. This strategic move aims to enhance the company's focus on developing new products and technologies. The subsidiary will operate entirely under the ownership of Bacil Pharma Limited, ensuring direct control over its research outcomes.

Key Details of the Proposed Subsidiary

The intimation was submitted to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mrs. Chaitali Kalpataru Shah, Director & CFO of Bacil Pharma Limited, signed the communication regarding the proposal.